StockData

Kymera Therapeutics vs Recursion Pharmaceuticals

KYMR and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KYMR and RXRX compare

Kymera Therapeutics is the larger company, worth 6.9 times as much as Recursion Pharmaceuticals ($10.7B against $1.6B).

Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −15.1% for Recursion Pharmaceuticals).

Kymera Therapeutics keeps more of each dollar of sales as profit, with a net margin of −342% compared with −946% at Recursion Pharmaceuticals.

Kymera Therapeutics scores higher on the StockData Score (9 against 8 for Recursion Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKYMRRXRX
Size and price
Market cap$10.7B$1.6B
Share price$125.85$2.90
Change, 1 year97.8%−32.9%
Change, 5 years134%−84.6%
Beta (5Y)0.542.37
Employees23850
StockData Score
Total score9 (better)8
Valuation score02 (better)
Growth score12 (better)
Performance score22
Health score6 (better)2
Dividend score00
Valuation
P/S105×28.4× (better)
P/B6.7×1.7× (better)
FCF yield−2.7% (better)−22.7%
Fair value$36.91$2.97
Margin of safety−241%2.1% (better)
Growth
Revenue growth (TTM)134% (better)−15.1%
Revenue growth, 5Y average2.9%79.9% (better)
Profitability
Gross margin0.00%3.5% (better)
Operating margin−396% (better)−992%
Net margin−342% (better)−946%
FCF margin−283% (better)−642%
Return on equity−27.3% (better)−56.6%
Return on invested capital−59.0% (better)−109%
Financial health
Debt / equity0.000.02 (better)
Interest coverage–−367.3×
Current ratio11.13 (better)5.03
Altman Z-score41.07 (better)−0.51
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield–−24.9%
Shareholder yield0.00% (better)−24.9%
Ownership
Held by institutions114%67.6%
Held by insiders38.3%5.6%
Insider net buying, 12 months−$301M−$7.4M (better)
Short interest, % of float16.0%28.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.